A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
A platform trial for severely ill patients with COVID-19. It aims to generate evidence that can be applied during the pandemic to reduce mortality, reduce ICU use, and reduce morbidity in severely ill patients with COVID-19 infection.
|Imperial PI||Professor Anthony Gordon (UK Lead)|
|Trial Sponsor||University Medical Center, Utrecht|
|Study status||In recruitment|
Find out more about this study here.